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Objective: The purpose of this study was to assess which clinical features of patients
with myasthenia gravis predict postoperative respiratory problems due to myas-
thenic crisis after transsternal thymectomy.
Methods: One hundred twenty-two patients who underwent transsternal thymec-
tomy in our institute were analyzed retrospectively. Fourteen of those experienced
myasthenic crisis and required prolonged (48 hours or more) postoperative mechan-
ical ventilation. The following factors were evaluated: sex, age, body mass index,
grade of symptom, disease interval, existence of thymoma, history of preoperative
crisis, doses of anticholinesterase drugs, steroid use, pulmonary function, serum
anti-acetylcholine receptor antibody, history of pulmonary disease, presence of
other disease, operation time, and blood loss.
Results: Univariate analysis revealed preoperative bulbar symptoms (odds ratio 
14.246, P  .001), history of preoperative myasthenic crisis (7.091, .018), and
preoperative serum level of anti-acetylcholine receptor antibody  100 nmol/L
(4.098, .044) were prognostic factors for postoperative myasthenic crisis. On the
other hand, multivariate logistic regression analysis revealed preoperative bulbar
symptoms (33.333, .004), preoperative serum level of anti-acetylcholine receptor
antibody  100 nmol/L (7.874, .020), and intraoperative blood loss  1000 mL
(18.519, .048) were prognostic factors for postoperative myasthenic crisis.
Conclusions: In this study, postoperative myasthenic crisis after transsternal
thymectomy in 122 patients with myasthenia gravis was affected by the existence of
preoperative bulbar symptoms, history of preoperative myasthenic crisis, preoper-
ative serum level of anti-acetylcholine receptor antibody  100 nmol/L, and
intraoperative blood loss  1000 mL. Meticulous preoperative and postoperative
care should be carried out to prevent postoperative myasthenic crisis in patients with
these prognostic factors.
Although patients with myasthenia gravis may develop respiratoryfailure for several reasons, it is very difficult to predict myastheniccrisis after transsternal thymectomy. Some scoring systems forpredicting myasthenic crisis have been reported by Leventhal andcolleagues1 and Kimura and coworkers,2 and they have beenapplied in the clinical field. However, the possible influence of
serum anti-acetylcholine receptor antibody (AchR-Ab) was not considered in these
systems. In our patients, these scoring systems could not always sufficiently predict
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the occurrence of postoperative respiratory failure in pa-
tients with myasthenia gravis. There are few studies on the
accurate analysis of prognostic factors for postoperative
myasthenic crisis, and therefore we sought to determine the
effects of clinical features of 122 patients with myasthenia
gravis in this study.
Materials and Methods
Patient Population and Variables Reviewed
Between January 1985 and December 2002, 122 consecutive pa-
tients underwent transsternal thymectomy for myasthenia gravis at
our hospital. The patients included 30 men and 92 women and the
mean age of 44  17 (15-77) years. Their clinical records were
reviewed regarding sex, age, body mass index (BMI), grade of
symptom (Osserman’s classification3), disease interval, existence
of thymoma, history of chronic pulmonary disease (pulmonary
emphysema, bronchial asthma, interstitial pneumonia, anthrasili-
cosis), history of preoperative crisis, preoperative daily dose of
anticholinesterase drugs (for convenience, 1 mg of ambenonium
chloride or 1 mg of distigmine bromide was considered as 8 mg of
pyridostigmine bromide), steroid use, Brinkman index (daily con-
sumption of cigarettes years smoked), pulmonary function (vital
capacity [VC], %VC, forced expiratory volume in 1 second
[FEV1.0], FEV1.0/forced VC [FEV1.0%] tidal volume), results of
arterial blood gas analysis (PaO2, PaCO2), serum AchR-Ab, resec-
tion status of thymoma, operation time, intraoperative blood loss,
operative procedure, and postoperative phrenic nerve palsy.
Preoperative Management
The preoperative regimen of anticholinesterase therapy was main-
tained until the time of operation. If the patient could not be
stabilized with medication, then preoperative plasmapheresis was
carried out. Plasmapheresis (blood adsorption) was performed for
7 patients in group I and 3 patients in group II with acute exacer-
bations and myasthenic crisis. The therapy was used for patients
with stable myasthenic symptoms even if their AchR-Ab levels
were high because we have no evidence that the therapy reduces
the occurrence of postoperative myasthenic crisis, and the cost of
these therapies is very high in Japan. Corticosteroids were tapered
at remission to the minimal dose required to maintain remission if
they were used. The patients with acute exacerbations and myas-
thenic crisis were not candidates for emergency operations, and
thymectomy was avoided until better medical control was gained.
Intravenous immune therapy was not carried out in this series.
Anesthetic Management
A thoracic epidural catheter was inserted in the Th5-6 or Th6-7
(thoracic vertebrae) interspace. Endotracheal intubation was per-
formed without muscle relaxants in all patients. General anesthesia
was induced, and this was followed by controlled ventilation with
isoflurane or seboflurane. Anesthesia was maintained with 50% to
60% nitrous oxide, 40% to 50% oxygen, and isoflurane (or
sevoflurane) with epidural bupivacaine (0.25%).
Surgical Procedure
The surgical procedure consisted of transsternal thymectomy be-
tween 1985 and 1990 and transsternal extended thymectomy4 after
1991. Three surgeons performed these operations in our hospital.
Dissection was performed bluntly from pericardium and pleura. If
necessary, the pleural cavity was opened and excluded. The bor-
ders of extended thymectomy were the diaphragm caudally, the
thyroid gland orally, and phrenic nerves laterally. One to 3 chest
tubes were placed in the thoracic cavity according to status of the
opening of mediastinal pleura. Three chest tubes were placed if
bilateral mediastinal pleurae were opened.
Anticholinesterase Therapy
Each patient underwent serial neurologic examination by a refer-
ring neurologist in the early postoperative period. Reinstitution of
anticholinesterase therapy was based upon the discretion of the
neurologist. Although 112 patients were given a lower dose (about
one third or half) of anticholinesterase agents postoperatively
compared with the preoperative dosage until the third or fourth
postoperative day, the other 10 patients were cases of Osserman’s
classification I who had a short suffering period or received only
corticosteroid therapy because of severe side effects to anticholin-
esterase agents, so they received no anticholinesterase agents pre-
operatively. Therefore, they were not given anticholinesterase
agents until the third or fourth postoperative day, unless their
symptoms deteriorated.
Postoperative Management
Analgesia was initially maintained with epidural bupivacaine
(0.25%) immediately after the operation. Before the patient recov-
ered from general anesthesia, arterial blood gas analysis was
performed while the patient spontaneously breathed oxygen-en-
riched air (fraction of inspired oxygen, FiO2  0.4). Extubation
was performed in the operating room or intensive care unit within
24 hours after the operation if possible. The extubation criteria for
weaning from mechanical ventilation were (1) clear consciousness,
(2) tidal volume of 5  body weight (kg) mL or more, (3) PaCO2
of 50 mm Hg or less under the condition of spontaneous ventila-
tion, (4) PaO2 of 90 mm Hg or more, and (5) respiratory rate of 30
breaths/minute or less. If the patient failed to meet these criteria,
mechanical ventilation was continued in the form of intermittent
mandatory ventilation, the rate being subsequently decreased to a
tolerable level, and extubation was later performed if the criteria
were met. The criteria for reintubation were (1) respiratory rate of
40 breaths/minute or more, (2) PaCO2 of 55 mm Hg or more, and
(3) tidal volume of 4  body weight (kg) mL or less.
Definition of Postoperative Myasthenic Crisis
Postoperatively all patients received chest physical therapy, in-
cluding incentive spirometry, chest clapping and squeezing, inter-
mittent positive-pressure breathing, aerosols, and endotracheal or
transnasal suctioning, if necessary. In this study, postoperative
myasthenic crisis was defined as total postoperative mechanical
ventilation support time of more than 48 hours with no postoper-
ative cardiopulmonary complications or cholinergic crisis. Respi-
ratory failures due to postoperative phrenic nerve palsies were
excluded from postoperative crisis. Postoperative phrenic nerve
palsies were diagnosed by the finding on chest roentgenogram on
fully inspiratory and expiratory phase and/or a phrenic nerve
conduction study (the phrenic nerve was cutaneously stimulated by
electrical pulse current at the midpoint of the posterior border of
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the sternomastoid muscle, and the diaphragmatic muscle com-
pound action potentials were recorded between the seventh and
eighth intercostal space and xiphoid process).5 The latter study was
performed only for the patients in group II while they had respi-
ratory failure. Myasthenic disorder was diagnosed by the neurol-
ogist using neurophysiological examination and/or provocative
diagnostic test using intravenous injection of edrophonium chlo-
ride (Tensilon).
Follow-up
The patients were evaluated 3 and 6 months and 1, 3, 5, and 10
years postoperatively. Their clinical status of myasthenia gravis
was assessed as: A, no symptoms without medication; B, increased
activity with less medication; C, no clinical change; D, more
medication, worse symptoms, or both; and E, death due to myas-
thenia gravis. The remission rate (RR) and palliation rate (PR)
were calculated according to the following formulas: RR  num-
ber of A/total number and PR  number of A  B/total number.6
Statistical Analysis
Statistical analyses were performed using SPSS 10.0 software
(SPSS, Inc, Chicago, Ill). All continuous data are expressed as a
mean  standard deviation of the mean. Categorical and contin-
uous variables were analyzed by the chi-square test (Fisher exact
test) as appropriate and by an unpaired Student t test, respectively.
Furthermore, continuous variables were converted into categorical
variables using each cutoff level and the ratio of the patients with
converted variable was compared in the 2 groups. Preoperative and
intraoperative variables were used for the determination of statis-
tically significant prognostic factors for postoperative myasthenic
crisis. Clinical factors found to have a P value of less than .20 in
the univariate analysis were entered into stepwise multiple logistic
regression analysis for the determination of statistically significant,
independent prognostic factors for postoperative myasthenic crisis.
Results
Groups
Fourteen of the 122 patients (11.5%) experienced postop-
erative myasthenic crisis. Two of those 14 patients were
unable to be extubated within 48 hours postoperatively, and
the other 12 patients underwent tracheal extubation early
but subsequently required tracheal reintubation because of
respiratory failure. Postoperative reintubation was per-
formed from postoperative days 1 to 17 (day 5 on average),
and mechanical ventilation support time averaged 4.8 days
(range 3-109). Three patients and 7 patients underwent
blood adsorption preoperatively and postoperatively, re-
spectively. Two patients required tracheostomy postopera-
tively due to long duration of respiratory failure. Tracheal
extubation after postoperative myasthenic crisis was suc-
cessful in all 14 patients. The patients were divided into 2
groups: group I consisted of 108 patients without postoper-
ative myasthenic crisis and group II consisted of 14 patients
with postoperative myasthenic crisis (Table 1).
Preoperative Factors
There were no significant differences between the 2 groups
in terms of age, sex ratio, BMI, and disease interval. The
number of patients with Osserman’s classifications of I, IIA,
IIB, and III or more were 25, 50, 28, and 5 cases in group
I and 1, 1, 8, and 4 in group II, respectively (P  .003).
Namely, 33 patients in group I and 12 patients in group II
had preoperative bulbar symptoms. Four patients in group I
and 3 patients in group II had a history of preoperative
myasthenic crisis. The ratio of patients with preoperative
bulbar symptoms and the ratio of patients with a history of
preoperative crisis were significantly higher in group II than
in group I. There were no significant differences between
the 2 groups in terms of preoperative daily dose of pyri-
dostigmine (156 vs 158 mg, P  .9670) and ratio of steroid
use (22/86 vs 4/10, P  .4945). The value of preoperative
AchR-Ab was significantly higher in group II than in group
I (35.5 vs 204.3 nmol/L, P  .0001). In preoperative serum
level of AchR-Ab, the cutoff level was made every 10
nmol/L from 10 to 100 nmol/L and the variable was con-
verted into categorical variable using the cutoff level; sig-
nificant difference was found to be greatest between the 2
groups when the cutoff level reached 100 nmol/L. There
were 11 patients with AchR-Ab of 100 or more nmol/L in
group I and 6 in group II, and the ratio of such patients was
higher in group II than in group I (P  .0046). The ratio of
patients with an existence of thymoma and history of
chronic pulmonary disease were similar in the 2 groups
(Table 2).
TABLE 1. Patients with postoperative myasthenic crisis (n
 14)
No. %
Failure of extubation  48
hours
2 14.3
Rerequirement of PMV after
weaning from PMV
12 85.7
Preoperative blood adsorption 3 21.4
Postoperative blood
adsorption
7 50.0
Postoperative tracheostomy 2 14.3
Timing of reintubation (day) 5.0 4.7 (1–17)
1–2 5 35.7
3–4 4 28.6
5–10 4 28.6
17 1 7.1
Duration of PMV (day) 4.8 2.3 (3–109)
3 5 35.7
4 3 21.4
5 2 14.3
6 4 28.6
PMV, Postoperative mechanical ventilation.
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Pulmonary Function and Blood Gas Analysis
Preoperative VC (3.03 vs 2.92 L, P  .687), FEV1.0 (2.55
vs 2.57 L, P  .929), and tidal volume (0.67 vs 0.62 L, P
 .471) were similar in the 2 groups. There were no
significant differences between the 2 groups with respect to
PaO2 (89.7 vs 87.7 mm Hg, P  .600) and PaCO2 (39.7 vs
41.5 mm Hg, P  .185). These continuous variables were
converted into categorical variables using each cutoff level
and the ratios of these converted variables in the 2 groups
were compared. There were no significant differences be-
tween the ratios in the 2 groups (Table 2).
Operative Factors
There were no significant differences between the 2 groups
with respect to operation time (174 vs 203 minutes, P 
.112) and amount of intraoperative blood loss (390 vs 393
mL, P  .979). These variables were converted into cate-
gorical variable using each cutoff level and the ratios of the
patients with these converted variables in the 2 groups were
compared. There were no significant differences between
the ratios in the 2 groups. An intraoperative blood loss 
1000 mL occurred in 4 patients in group I and 2 patients in
group II. All the patients except 1 had invasive thymoma.
Bleeding occurred in the other patient following injury of a
left brachiocephalic vein. Resection status of thymoma
(complete vs incomplete, P .322) and the type of thymec-
tomy (thymectomy vs extended thymectomy, P  .758) did
not influence occurrence of postoperative myasthenic crisis
(Table 2).
Postoperative Respiratory Complications
Postoperative phrenic nerve palsies due to intraoperative
phrenic nerve injury were diagnosed in 5 patients in group
I but no patients in group II. All patients except 1 had
thymomatous myasthenia gravis. Five patients in group I
and 1 patient in group II developed pneumonia. One patient
in group I died from pneumonia 2 months after thymec-
tomy. One patient in group I had hemothorax requiring
reoperation for hemostasis. There were no residual pneu-
mothoraxes or pulmonary embolisms in either group.
TABLE 2. Clinical data
Variable
Postoperative crisis P
value(): Group I (n  108) (): Group II (n  14)
Sex (men/women) 26/82 4/10 .7448
Age (y) 44 16 (15–77) 47 19 (20–77) .561
BMI 22.9 3.9 (16.8–37.8) 21.1 3.0 (16.8–26.6) .107
20 27 (25.0%) 5 (35.7%) .5181
Osserman’s classification
I 25 1
IIA 50 1 .0001
IIB 28 8
IIIIV 5 4
Bulbar symptoms 33 (30.6%) 12 (85.7%) .0001
Disease interval (y) 3.4 5.9 (0.06–36.9) 1.7 2.4 (0.09–8.21) .311
Thymoma 24 (22.2%) 5 (35.7%) .3173
Pulmonary disease 4 (3.7%) 1 (7.1%) .4622
Preoperative crisis 4 (3.7%) 3 (21.4%) .0324
Preoperative dosage of pyridostigmine (mg) 156 148 (0–840) 158 126 (0–450) .967
Preoperative steroid use 22 (20.4%) 4 (28.6%) .4945
Brinkman index 147 346 (0–1980) 157 218 (0–585) .921
VC 3.03 0.88 (0.87–5.22) 2.92 0.91 (1.52–4.40) .687
%VC 102.8 20.1 (38.4–149.4) 94.8 10.3 (76.0–109.3) .181
FEV1.0 2.55 0.83 (0.44–4.99) 2.57 0.90 (0.80–3.89) .929
FEV1.0% 86.1 12.1 (50.5–134.7) 83.0 13.5 (56.3–98.2) .419
TV 0.67 0.23 (0.23–1.36) 0.62 0.19 (0.41–1.08) .471
PaO2 89.7 10.1 (62.3–100.0) 87.7 14.6 (55.9–100.0) .600
PaCO2 39.7 3.5 (31.7–47.9) 41.5 4.5 (29.8–46.9) .185
AchR-Ab level (nmol/L) 35.5 67.2 (5.2, 0–404) 204.3 344.1 (9.3, 0–1100) .0001
100 11 (10.2%) 6 (42.9%) .0046
Operation time 174 55 (45–365) 203 98 (110–475) .112
Blood loss 390 67 (60–3600) 393 302 (150–1100) .979
Resection status of thymoma, incomplete resection 8 (7.4%) 2 (1.4%) .322
Thymectomy/extended thymectomy 32/76 5/9 .758
Phrenic nerve palsy 5 (4.6%) 0 (0.0%) .5837
BMI, Body mass index; DI, disease interval; VC, vital capacity; FEV, forced expiratory volume; TV, tidal volume; AchR-Ab, anti-acethylcholine receptor
antibody.
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Follow-up Results
Follow-up results are summarized in Table 3. There are no
significant differences between group I and group II regard-
ing RR and PR after 3 and 6 months and 1, 3, 5, and 10
years after thymectomy.
Univariate Logistic Regression Analysis
Variables that had P values of less than .05 between the 2
groups were preoperative bulbar symptoms (odds ratio 
14.246, P .001), history of preoperative myasthenic crisis
(7.091, 0.018), and preoperative serum level of AchR-Ab
100 nmol/L (4.098, 0.044) (Table 4).
Multivariate Logistic Regression Analysis
Clinical factors found to have a P value of less than .20 in
the univariate analysis were entered into stepwise multi-
variate logistic regression analysis for the determination
of statistically significant independent prognostic factors
for postoperative myasthenic crisis. These factors were:
preoperative bulbar symptoms, history of preoperative
myasthenic crisis, preoperative serum level of AchR-Ab
 100 nmol/L, intraoperative blood loss  1000 mL, age
 70 years, FEV1.0  1.2 L, and existence of thymoma.
Multivariate analysis revealed preoperative bulbar symp-
toms (odds ratio  33.333, P  .004), preoperative
serum level of AchR-Ab  100 nmol/L (7.874, 0.020),
and intraoperative blood loss  1000 mL (18.519, 0.048)
to be prognostic factors for postoperative myasthenic
crisis (Table 5).
Limitations of This Study
The major limitation of the present study was that all data
were analyzed retrospectively, a process that mandates cau-
tion in the interpretation of the results. There may be some
differences in operative procedure because these serial
thymectomies were carried out by 3 surgeons over a long
period (17 years). Moreover, the number of patients may not
be large enough for evaluation by multivariate logistic re-
gression analysis.
Discussion
Myasthenia gravis is an autoimmune disease characterized
by the production of autoantibodies directed against the
acetylcholine receptor of the neuromuscular synapse. Auto-
antibodies directed against the AchR of the motor end plate
can be detected in about 85% of all affected patients. In the
remaining 15%, antibodies with specificities to other muscle
targets (ryanodine receptor, titin) are involved, which are
not detected with the standard assay.7 Four treatment mo-
dalities are used: anticholinesterase agents to preserve ace-
tylcholine in the synaptic spaces, surgical thymectomy,
immunosuppression, and short-term immunotherapies that
include phycoerythrin and intravenous immunoglobulin.
Treatments directed toward immune regulation improve
functional status and reduce the risk of exacerbation. Some
exacerbations, called myasthenic crisis, involve the respira-
tory muscle and are life-threatening. Myasthenic crisis oc-
curs in 15% to 20% of patients with myasthenia gravis and
is more frequent in the first 2 years of disease.8
The nicotinic AchR is the substrate of the autoimmune
response. The AchR is a glycoprotein composed of 5 sub-
units.9 Each molecule consists of 2 alpha subunits, 1 beta
unit, 1 delta subunit, and 1 gamma epsilon subunit. Auto-
antibodies are directed at all 5 units but predominantly at the
sequences of the alpha subunit, leading to acceleration of
the normal degradation of the receptors. In some patients,
antibodies may be directed at a site on the alpha subunit
different from the major immunogenic subunit. The exact
role of this group of potent antibodies is not known but is
thought to contribute to development of myasthenic crisis or
rapid worsening of muscle strength.10 Certain components
TABLE 3. Remission and palliation rates in patients with myasthenia gravis after thymectomy
Time after thymectomy
3 months 6 months 1 year 3 years 5 years 10 years
Number
Group I 107 107 99 87 72 48
Group II 14 14 13 11 10 5
RR (%)
Group I 13.1 14.9 20.2 35.6 38.9 41.7
Group II 14.3 14.3 23.1 18.2 30.0 40.0
P value .999 .999 .728 .325 .735 .999
PR (%)
Group I 67.2 76.6 82.8 83.9 86.1 93.8
Group II 71.4 78.6 84.6 81.8 90.0 80.0
P values .999 .999 .999 .999 .999 .335
RR, Remission rate; PR, palliation rate. There are no significant differences between group I and group II regarding to RR and PR in 3 and 6 months and
1, 3, 5, and 10 years after thymectomy.
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of the complement system are thought to potentiate the
degeneration of the acetylcholine receptors. The comple-
ments C3, C9, and C5-9 activation neoantigens are capable
of membrane lysis and are detected at the end plate in
myasthenia gravis.11,12 Infections, reduction in medication,
menstruation, exposure to toxic substances, emotional fac-
tors, surgery, thyroid diseases, reactions to contrast agents
used with computed tomography of the chest, and the use of
some medications (aminoglycosides, tetracycline, muscle-
relaxing agents, chloroquine, quinine, lithium, chlorproma-
zine, diazepam, opioids, barbiturates, corticosteroids, thy-
roxin, and others) are implicated in the development of
crisis.13,14
Despite the well-documented role of AchR-Abs in my-
asthenia gravis, serum levels of AchR-Ab do not correlate
with myasthenic crisis13,14 or the severity of disease.15
There are few reports16 on the relationship between serum
levels of AchR-Ab and the development of myasthenic
crisis following transsternal thymectomy. The present re-
sults show that high serum levels of AchR-Abs were impli-
cated in the development of myasthenic crisis after trans-
sternal thymectomy. Our results do not contradict the results
TABLE 4. Univariate regression analysis
Variable
Odds
ratio 95% CI P value
Age
50 year 1.919 0.630–5.882 .254
60 year 1.130 0.289–4.405 .861
70 year 4.329 0.717–26.316 .110
Sex, female 0.793 0.229–2.741 .714
BMI  20 1.667 0.512–5.435 .396
DI
6 years 2.688 0.331–21.739 .355
10 years 1478.078 0.000–5.505E28 .808
Preoperative bulbar symptom 14.246 3.015–67.300 .001
Brinkman Index  400 0.681 0.128–3.623 .653
VC  2.9L 0.980 0.275–3.522 .984
% VC
80% 0.720 0.141–3.685 .694
70% 0.002 0.000–5.153E16 .783
FEV1.0  1.2 L 3.500 0.566–21.647 .178
FEV1.0%  70% 1.591 0.162–15.579 .690
History of plumonay disease() 2.000 0.207–19.231 .549
History of myasthenic crisis 7.091 1.402–35.859 .018
Dosage of prestigmine 300 mg/d 484.173 0.0–1.354E22 .787
Complete resection 0.480 0.081–2.527 .386
Preoperative steroid use 0.844 0.212–3.356 .810
Operation time  180 min 0.665 0.206–2.141 .494
Blood loss
500 mL 0.503 0.139–1.828 .297
1000 mL 4.049 0.663–25.000 .130
AchR-Ab level (nmol/L)
0.04 1.538 0.318–7.435 .592
10 1.776 0.573–5.525 .319
50 3.112 0.967–10.101 .057
100 4.098 1.042–16.129 .044
Thymoma () 2.625 0.830–8.303 .100
BMI, Body mass index; DI, disease interval; VC, vital capacity; FEV, forced expiratory volume; AchR-Ab, anti-acethylcholine receptor antibody.
TABLE 5. Stepwise multivariate logistic regression analysis
Variable Coefficient  SE Odds CI P value
Preoperative bulbar symptom 3.508 1.207 33.333 3.135–333.333 .004
AchR-Ab level  100 (nm/L) 2.062 0.886 7.874 1.383–45.455 .020
Blood loss  1000 mL 2.917 1.477 18.519 1.022–333.333 .048
AchR-Ab, Anti-acethylcholine receptor antibody.
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in previous reports because our patients who developed
myasthenic crisis have immunological disorders, especially
regarding the complements following physiological and
emotional stress due to transsternal thymectomy. In such
cases, high levels of AchR-Abs might be directed at a site
on the alpha subunit different from the major immunogenic
subunit and cause myasthenic crisis. In fact, 0 to 50 nmol/L
of AchR-Abs affected the occurrence of myasthenic crisis
after transsternal thymectomy in our series. The death rate
of myasthenic crisis has drastically decreased since the
1950s, from 80% to less than 10%, thanks to the use of early
mechanical ventilation, admission of the myasthenic patient
to an intensive care unit, recognition and treatment of pre-
cipitating factors, edrophonium testing, use of anticholines-
terase drugs, steroid therapy, immunosuppression, plasma-
pheresis,17,18 and intravenous human gamma globulin.7,19
We have sometimes seen patients with myasthenic crisis
after transsternal thymectomy for myasthenia gravis. The
incidence of myasthenic crisis after transsternal thymec-
tomy varies from 6.0% to 34%.20-22 The comparison of
meager data was very difficult because the criteria applied
for the calculation of the incidence rates of respiratory
insufficiency were not accurately described in any article
except one by Kas and coworkers.22 Their study showed
that 65 (33.6%) of 193 patients who underwent transsternal
simple or extended thymectomy developed respiratory fail-
ure (defined the same as in our study). The incidence of
postoperative respiratory failure in their series is higher than
in ours (11.5%).
Many methods for postoperative management of myas-
thenia gravis patients have been reported over the years.
Regarding postoperative mechanical ventilation, early
workers advocated tracheostomy in all cases, with careful
weaning from ventilation.23,24 Kas and colleagues22 advo-
cated anticholinesterase medication, which was withdrawn
for the 48 hours of obligatory postoperative mechanical
ventilation. We think that postoperative routine ventilatory
support is never necessary and complete withdrawal of
anticholinesterase drugs, if they were used for the patient
preoperatively, might induce myasthenic crisis despite pre-
venting cholinergic crisis, because the incidence of postop-
erative respiratory failure in their series is higher as men-
tioned above. On the other hand, Gorback and colleagues25
advocated early extubation after transsternal thymectomy.
They reported that appropriate criteria for weaning from
mechanical ventilation, first measured at the end of anes-
thesia, were PaO2  90 mm Hg under FiO2 of 0.4, PaCO2 
50 mm Hg, pH  7.30, and respiratory rate  30 breaths/
minute, and appropriate criteria for extubation were meeting
the criteria for weaning, vital capacity  10 mL/kg, and
inspiration pressure better than 30 cm H2O. In addition,
they reported in their prospective analysis that if extubation
was performed on the basis of the criteria, although VC at
the time of extubation decreased to approximately 50% of
preoperative VC, no patients required reintubation after
transsternal thymectomy for myasthenia gravis. These cri-
teria seemed to be useful to reduce inappropriate postoper-
ative pulmonary management, but no effective strategy for
treating the patients with myasthenic crisis was shown.
The perioperative use of anticholinesterase drugs re-
mains controversial. Pego-Fernandes and colleagues26 ad-
vocated 50% reduction in the administration of anticholin-
esterase drugs on the first postoperative day. On the other
hand, Kas and colleagues22 advocated cessation of the drugs
for 48 hours after thymectomy. The former emphasis was on
reducing the occurrence of myasthenic crisis and the latter
on reducing the occurrence of cholinergic crisis. We think
that a randomized controlled trial is required to assess the
effect of postoperative use of anticholinesterase drugs on
respiratory failure. If prognostic factors for postoperative
myasthenic crisis can be accurately detected preoperatively,
it would greatly contribute to the perioperative management
of patients with the factors. If proper preoperative and
postoperative management is performed, it might be enable
us to reduce occurrence of postoperative myasthenic crisis
and reduce cases of unnecessary mechanical ventilation
support or inappropriate weaning from mechanical ventila-
tion after transsternal thymectomy.
Gracy and colleagues17 reported that the grade of preop-
erative bulbar symptoms is the only predictive factor for
myasthenic crisis after transsternal thymectomy. On the
other hand, Loach and colleagues27 reported that preopera-
tive vital capacity of less than 2.0 L, presence of thymoma,
presence of preoperative bulbar symptoms, and age of more
than 50 years influenced myasthenic crisis. Leventhal and
colleagues1 established a scoring system to predict require-
ment for postoperative mechanical ventilation after thymec-
tomy by evaluation of 24 patients. In this system, 12 points
are assigned to disease interval  72 months, 10 points to
history of respiratory disease, 8 points to dosage of pyri-
dostigmine 750 mg/d, and 4 points to VC 2.9 L. A total
score of 10 or more points predicted the requirement for
postoperative mechanical ventilation. Although prognostic
factors for postoperative myasthenic crisis have been re-
ported and used in clinical management,1,2 the possible
influence of serum AchR-Ab was not considered in these
reports despite its wide clinical use as a diagnostic param-
eter of myasthenia gravis.
We evaluated the effects of clinical features of patients
with myasthenia gravis and the effect of serum AchR-Ab on
postoperative myasthenic crisis. Univariate analysis in the
present study indicated that 3 preoperative factors influ-
enced myasthenic crisis after transsternal thymectomy in
patients with myasthenia gravis: (1) existence of preopera-
tive bulbar symptoms, (2) history of preoperative myas-
thenic crisis, and (3) preoperative serum AchR-Ab  100
General Thoracic Surgery Watanabe et al
874 The Journal of Thoracic and Cardiovascular Surgery ● March 2004
G
TS
nmol/L. On the other hand, multivariate logistic regression
analysis revealed existence of preoperative bulbar symp-
toms, preoperative serum level of AchR-Ab  100 nmol/L,
and intraoperative blood loss  1000 mL were prognostic
factors for postoperative myasthenic crisis. Although it is
not clear how intraoperative blood loss  1000 mL affects
postoperative myasthenic crisis, stress and immune disorder
caused by a large amount of blood loss might be associated.
Although the risk of respiratory failure may have been
decreased by using less invasive surgical approaches (cer-
vicotomy,28-30 partial sternotomy,26 or video-assisted tho-
racoscopic surgery31,32), avoiding myorelaxants and long-
acting anesthetic agents, and providing adequate
postoperative analgesia,33,34 the accurate incidence rate of
postoperative myasthenic crisis was not described in these
reports. Contraindications to cervical thymectomy include
advanced age, poorly controlled neurologic symptoms, and
evidence for a thymoma. The procedure is associated with
negligible morbidity and requires only a brief hospitaliza-
tion.35 We must give careful consideration to the point that
these procedures remain controversial as to the response
rate.
A report by Papatestas and colleagues28 on 788 nonthy-
momatous patients who underwent transcervical thymec-
tomy revealed that the remission rate at 5 years was 23%.
Pego-Fernandes and colleagues26 reported that thymectomy
by partial sternotomy for the treatment of myasthenia gravis
revealed that the complete remission rate and improvement
rate were 12.7% and 79.9%, respectively. (They did not
describe at what time after thymectomy they calculated
these rates.) These results are inferior to ours. On the other
hand, Meyers and colleagues29 and Shrager and col-
leagues30 recently demonstrated that response rates after
transcervical thymectomy were equivalent to the transster-
nal approach (remission rate at 5 years after the thymectomy
was 43% and 44%, respectively) with significantly less
morbidity and only a rare instance of postoperative myas-
thenic crisis. In all cases, it is important to decrease post-
operative mortality and morbidity and to increase response
rate after thymectomy.
Gracy and colleagues17 and Mahalati and colleagues18
revealed that plasmapheresis effectively improved myas-
thenic crisis. We attempted preoperative plasma adsorption
in 2 patients who recently had extended thymectomy for
myasthenia gravis and who had 2 or more of the prognostic
factors for postoperative myasthenic crisis. Although their
myasthenic symptoms improved after the adsorption ther-
apy and preoperative serum level of AchR-Ab reduced to a
level below 100 nmol/L, 1 of them required prolonged
postoperative mechanical ventilation after transsternal
thymectomy due to myasthenic crisis. This result indicates
that single plasma adsorption therapy is not always effective
in preventing postoperative myasthenic crisis.
Recently, the efficacies of new immunomodulatory ther-
apies, such as double filtration plasmapheresis and intrave-
nous immunoglobulin maintenance therapy, for patients
with myasthenia gravis have been reported.36,37 The pro-
phylactic efficacy of these therapies on postoperative my-
asthenic crisis still remains controversial. Establishment of
effective preoperative and postoperative management is
needed to reduce or eliminate postoperative myasthenic
crisis.
In conclusion, existence of preoperative bulbar symp-
toms, history of preoperative crisis, serum AchR-Ab  100
nmol/mL, and intraoperative blood loss  1000 mL influ-
ence occurrence of myasthenic crisis after transsternal
thymectomy. In patients with these prognostic factors, care-
ful preoperative and postoperative management should be
carried out to prevent postoperative myasthenic crisis. Fur-
ther study is needed to establish the effective preoperative
and postoperative management for patients undergoing
transsternal thymectomy for myasthenia gravis.
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